By Chase Doyle
FORT WORTH, TEXAS—Although the emergence of sorafenib in the front-line setting for hepatocellular carcinoma (HCC) has changed practice, many clinicians continue to debate the best second-line agent from a multitude of options. At the 2019 Hematology/Oncology Pharmacy Association annual meeting, Julianne Orr, PharmD, discussed factors to consider when evaluating the tyrosine kinase inhibitors and immune checkpoint inhibitors used in second-line therapy for patients